Phase II Study of Taselisib in PIK3CA -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.

Several tumor types, including adenoid cystic carcinoma and squamous cell carcinomas of the head and neck, showed some evidence of tumor size reductions in all or most patients, although the sample sizes were small for each group (Fig 3). Consistent with the tumor agnostic NCI-MATCH trial platform and the Arm I-specific exclusion of breast and squamous cell lung cancer, patients with 37 distinct tumor histologies were enrolled. Patients with prior cancers who were disease-free for 5 years, or adequately treated basal or squamous cell skin cancer, in situ cervical cancer, or adequately treated other stage I or II cancer in complete remission were permitted. Most AEs were grade 1 and 2, although 19 of 66 (29%) patients experienced grade 3 AEs, one patient (2%) experienced grade 4 hyperglycemia, and two patients had grade 5 AEs (sudden death and neoplasm). [Extracted from the article]